Pediatric high-grade astrocytomas: a distinct neuro-oncological paradigm

Noha Gerges1, Adam M Fontebasso2, Steffen Albrecht3, Damien Faury1 and Nada Jabado*1,2

Abstract

Brain tumors are the leading cause of cancer-related death in children. High-grade astrocytomas (HGAs), in particular, are lethal in children across all ages. Integrative genome-wide analyses of the tumor’s genome, transcriptome and epigenome, using next-generation sequencing technologies and genome-wide DNA methylation arrays, have provided valuable breakthroughs in our understanding of the pathogenesis of HGAs across all ages. Recent profiling studies have provided insight into the epigenetic nature of gliomas in young adults and HGAs in children, particularly with the identification of recurrent gain-of-function driver mutations in the isocitrate dehydrogenase 1 and 2 genes (IDH1/2) and the epigenetic influence of their oncometabolite 2-hydroxyglutarate, as well as mutations in the histone 3 variant 3 gene (H3F3A) and loss-of-function mutations in the histone 3 lysine 36 trimethyltransferase gene (SETD2). Mutations in H3F3A result in amino acid substitutions at residues thought to directly (K27M) or indirectly (G34R/V) affect histone post-translational modifications, suggesting they have the capacity to affect the epigenome in a profound manner. Here, we review recent genomic studies, and discuss evidence supporting the molecular characterization of pediatric HGAs to complement traditional approaches, such as histology of resected tumors. We also describe newly identified molecular mechanisms and discuss putative therapeutic approaches for HGAs specific to pediatrics, highlighting the necessity for the evolution of HGA disease management approaches.

Astrocytomas differ in brain location and tumor grade across age

Today, primary brain tumors constitute the leading cause of cancer-related mortality in children and adolescents aged 20 years and under, now surpassing leukemia, and the third leading cause of cancer-related death in young adults aged 20 to 39 years [1]. These brain tumors have a devastating socio-economic impact on patients and their families, with significant disease and treatment effects and healthcare costs, and with many if not most patients with higher-grade tumors dying after enduring the 1 to 3 year course of their cancer and the side effects of their therapies.

Gliomas are the most common primary central nervous system tumors in both children and adults [2]. This heterogeneous group of tumors is classified by the World Health Organization (WHO) [3] into four major groups: astrocytomas; oligodendrogliomas; mixed oligoastrocytomas; and ependymal tumors. They are then further segregated into distinct histological grades, ranging from WHO grade I to grade IV on the basis of defined cytologic and histologic features, including cellularity, mitotic activity, nuclear atypia, microvascular proliferation and necrosis (Table 1) [3]. The most important prognostic factors across the age spectrum are tumor grade, age at diagnosis, and completeness of surgical resection [2,4]; however, glioblastoma multiforme (GBM, grade IV astrocytoma) remains essentially incurable despite decades of concerted therapeutic efforts.

The tumor location, pathological subtype and tumor grade, as well as the potential for a stepwise progression from lower to higher grade, have been shown to vary with age (Figure 1). For example, oligodendrogliomas and high-grade gliomas (HGGs) are less common in children [2]. By contrast, grade I astrocytomas - termed pilocytic astrocytomas (PAs) - are the most common primary brain tumor in childhood, accounting for approximately 25% of all pediatric brain tumors [2,3]. They arise most frequently in the cerebellum, followed by the optic pathways, where they occur as sporadic tumors or in the context of neurofibromatosis type I, followed by the brainstem, thalamus and the spinal cord. Conversely, PAs rarely arise in the cerebral hemispheres or in patients older than 18 years [2,5].
Table 1. Classification of pediatric and adult brain tumors

| Tumor type       | Subtype          | Grade | Histology                                                                 | Location                                                                 | Prevalent age group | Therapy                                                                 | Prognosis                        |
|------------------|------------------|-------|---------------------------------------------------------------------------|---------------------------------------------------------------------------|---------------------|--------------------------------------------------------------------------|----------------------------------|
| Astrocytomas     | Pilocytic astrocytoma | I     | Pilocytic cell morphology, less infiltrative, low proliferative activity. | Cerebellum, optic pathway, brainstem, thalamus and spine.                | Children (0 to 16) | Surgical resection, adjuvant therapies considered in the case of incomplete surgical resection. | Excellent (100% 5-year survival; 96% 10-year survival) |
| Diffuse astrocytoma | II               |       | Infiltrative with low proliferative potential but often recurs. Can progress to higher grades in adults. | Cerebrum, optic pathway, brainstem, hypothalamus, thalamus and spine. | Young adults (20 to 39 years) | Surgery, adjuvant therapies considered on a case by case basis. | Moderate (58% 5-year survival) |
| Anaplastic astrocytoma | III              |       | Infiltrative, with nuclear atypia and higher mitotic activity.             | Cerebrum, cerebellum, brainstem and spine.                               | Adults              | Surgical resection when possible, followed by adjuvant radiation and chemotherapy. | Poor (11% 5-year survival) |
| Glioblastoma multiforme | IV              |       | Infiltrative, nuclear atypia, high mitotic activity, pseudopalisading necroses, florid microvascular proliferation. | Cerebrum, cerebellum and spine, but brainstem glioblastoma multiforme (DIPGs) are more frequent in children. | Adults, except DIPG, which is prevalent in children below 10 years of age | Surgical resection when possible, followed by adjuvant radiation and chemotherapy. | Very poor (1.2% 5-year survival) |

DIPG, diffuse intrinsic pontine glioma.

WHO grade II (diffuse) astrocytomas are more common in younger adults and usually progress to higher-grade tumors, that is, to anaplastic astrocytoma and secondary GBM in adults, whereas stepwise progression is rarely reported in children [6]. The majority of GBM tumors, however, are primary tumors that arise de novo and typically manifest in older patients (older than 60 years), where they account for the most common type of primary central nervous system tumor in that age group. In adults, gliomas occur mostly as supratentorial tumors, mainly in the cerebral cortex and the thalamus [1-3,5,7] (Figure 1). HGAs in children represent less than 15% of all primary central nervous system neoplasms and encompass tumors mainly located in supratentorial regions including the cortex and the thalamus, similar to adult high-grade tumors, but also in the brainstem, a tumor location that is almost exclusive to children, where they are named diffuse intrinsic pontine gliomas (DIPGs) [8]. The vast majority of pediatric GBM tumors will arise de novo, without evidence of a pre-existing lower-grade lesion and subsequent tumor progression to secondary GBM, in contrast to young adults with this disease.

Genetic alterations in gliomas vary according to age, histology and tumor grade

The neuroanatomical specificity of particular tumor subtypes within adult and pediatric age groups suggests that important, intrinsically unique biological factors, such as developmental constraints, cellular origin and tumor microenvironment, may contribute to specific forms of gliomagenesis in distinct brain regions [9-11]. Importantly, this is exemplified in PA, which has been described as essentially a ‘single-pathway’ disease with defects primarily affecting the mitogen-activated protein kinase (MAPK) pathway, most commonly with defects in BRAF [12-18], a serine-threonine kinase member of the RAF kinase family that regulates MAPK signaling. Duplication of BRAF at chromosomal region 7q34 was shown to define the majority of PAs [18], and was further characterized in association with the formation of a variety of in-frame fusions between KIAA1549 and BRAF [14]. These fusions invariably lead to the loss of the N-terminal regulatory domain and/or constitutive activation of the RAF kinases, resulting in increased MAPK pathway signaling. The mechanism leading to 7q34 duplication and BRAF fusions, a defining feature of PAs, is unclear. Recent studies suggest that the process of microhomology-mediated break-induced replication may be involved in the generation of these structural rearrangements [19].

Interestingly, although KIAA1549-BRAF fusion was shown to characterize the vast majority of PA tumors, notably of the cerebellum and optic pathways [12], other mutations/alterations – or ‘hits’ – leading to activation of the MAPK pathway have been described, such as the BRAF V600E mutation, NF1 mutation or loss (in
neurofibromatosis-type-1-associated PA), and other RAF-family fusions, usually observed in non-cerebellar PA tumors [14-17]. Recently, Zhang et al. and Jones et al. described MAPK pathway hits in 95 to 100% of PAs, demonstrating the central importance of targeting specific pathway alterations in this tumor type [20,21]. This is of importance because Braf and the MAPK pathway have been shown to have a key role in cerebellar development, with neural stem cells (NSCs) in this region demonstrating proliferation in response to expression of KIAA1549-BRAF, whereas NSCs in regions of the neocortex, for instance, do not (reviewed in [18,22]), paralleling incidence rates of KIAA1549-BRAF fusions detected in human tumors. These findings are being translated into clinical practice, as phase I/II clinical trials are currently assessing the benefit of using MAPK inhibitors in cases where adjuvant therapies are required [23]. In the context of low-grade diffuse astrocytoma, recent studies by Ramkissoon et al. have uncovered a chromosomal gain at 8q.13.1 in 28% of diffuse astrocytoma patients (grade II) that leads to a partial duplication of MYBL1 with a simultaneous truncation of its C-terminal negative regulatory domain [24]. This lends insight into other molecular events that predominate in low-grade gliomas.

Prognosis of HGGs has remained dismal despite decades of concerted therapeutic efforts. Current therapy across age comprises resection if possible, followed by radiotherapy. Adjuvant therapies include the alkylating agent temozolomide [25,26] and targeted therapeutic inhibitors, such as EGFR against receptor tyrosine kinases (RTKs) [27] and bevacizumab against the angiogenic factor VEGF-A [28,29]. All demonstrate minimal impact on survival (Table 1) [2-4]. Here, we present an in-depth discussion of recent studies utilizing high-throughput genome-wide methods such as next-generation sequencing, and integrating data with gene expression profiling, DNA methylation and copy number analysis in HGGs, with a focus on GBM across the age spectrum. These studies shed light on novel molecular

---

**Figure 1. Overview detailing the differences between astrocytomas in the pediatric and adult age groups.**

(a) Depiction of grade distribution in adults and children highlighting that the majority of astrocytomas in adults are grade IV astrocytomas (glioblastomas), whereas the majority in the pediatric years are grade I astrocytomas (pilocytic astrocytomas).  
(b) Depiction of tumor localization. In adults, astrocytomas are most likely to arise in the cortex and the thalamus whereas in the pediatric years, astrocytomas are most common in the cerebellum, optic nerve and brainstem.  
(c) Age distribution between the four astrocytoma grades in adults and children. Grade and age data summarized from [5].
mechanisms and provide arguments for a paradigm shift in GBM treatment that will hopefully translate into individualized patient management and ultimately better therapeutic success for this deadly group of diseases.

**Children are not simply ‘young’ adults: genomic and epigenomic analyses reveal clinical and biological subgroups of glioblastoma**

Genome-wide technologies including sequencing, copy number analysis and gene expression profiling have revolutionized the analysis and subgrouping of tumors, including primary central nervous system tumors such as medulloblastoma [30-39], posterior fossa ependymoma [40] and GBM [9,41-46]. The Tumor Cancer Genome Atlas (TCGA) has been central in defining the molecular heterogeneity of adult GBM tumors and HGGs [41,42,46]. Initial efforts focused on the sequencing of 600 candidate genes in 206 adult GBM tumors and identified somatic mutations in key tumor suppressor genes such as TP53, PTEN, NF1, RB and PIK3R1, as well as in the oncogenes EGFR, ERBB2 and PIK3CA [46] (Table 2). These and other large-scale sequencing efforts also identified recurrent, somatic, gain-of-function mutations in IDH1/2 (encoding isocitrate dehydrogenases of the citric acid cycle), which were shown to characterize the vast majority of adult secondary GBM tumors, but were rare in de novo/primary GBM tumors [47,48]. Patients with IDH mutations were younger adults (age range from 25 to 53 years in [47] and from 13 to 71 years in [9]) and had a better overall survival [47]. Identification of IDH mutations in lower-grade diffuse gliomas and secondary GBM tumors suggests that such a mutation might be an early initiating event in gliomagenesis that is also important in tumor progression [47-49]. Further integrated molecular analysis allowed the identification in adult GBM tumors of four expression subgroups defined by mutation/alteration in PDGFRα, EGFR, IDH1 and NF1 [41]. Verhaak and colleagues utilized an 840-gene signature to cluster adult GBM tumors into four subgroups, each defined by a gene expression subset encompassing neurodevelopment, traditional cancer-associated pathways or markers of differentiation [41]. Further investigation into the epigenomes of HGGs through the analysis of global DNA methylation analysis led to the identification of three epigenetic clusters, one of which demonstrated global hypermethylation and was largely defined by IDH mutations with a ‘proneural’ gene signature, the CpG-island hypermethylator phenotype, G-CIMP [42].

Although pediatric and adult HGGs are indistinguishable under the microscope [50], recent molecular characterization has demonstrated that they are in fact distinct molecular entities. Age-related differences in GBM tumors and HGGs are evident when considering molecular profiling studies based on global gene expression and copy number analysis [44,51,52]. In pediatric GBM tumors, which occur largely de novo, IDH1, EGFR, PTEN and other classic driver mutations and alterations identified in adult GBM tumors are rare, affecting mainly adolescents [10,51] (Table 2), indicating that other critical elements are involved in pediatric gliomagenesis. Our group was able to characterize the differences in global gene expression between pediatric and adult GBM tumors and demonstrated that RAS/AKT activation correlates with worse overall survival in pediatric GBM [44]. In addition, overexpression of Y-box protein 1 (YB-1) was common to most pediatric GBM tumors, demonstrating age-related differences in brain tumors, as well as within-age-group heterogeneity when considering RAS/AKT clinical correlates [44,45]. Integrated copy number and gene expression profiling studies also suggest intrinsic biological differences in pediatric HGGs, notably with respect to the rarity of EGFR amplification or its recurrent gain-of-function variant (EGFRvIII), which occur frequent in adult GBM [51]. However, in pediatric GBM tumors, including DIPGs, PDGFRα amplification was detected in 10 to 15% of samples, with an increased frequency of 30% in irradiation-induced tumors, suggesting an early initiating role of this mutation in pediatric HGG tumorigenesis [51] (Table 2). In addition, the spectrum of high-level focal amplifications and homozygous deletions is also unique in pediatric and adult age groups (Table 2).

Although limited EGFR amplification is present in pediatric GBM, overexpression of this RTK, PDFRα and MET, another RTK, have been identified in a substantial number of cases, especially in DIPG, indicating that similar signaling pathways are activated, albeit through distinct molecular triggers.

However, similar to in adults, several clinical trials aiming to target these kinases in children have had limited therapeutic success [2], which may be partly due to poor bioavailability in the brainstem in addition to blood-brain barrier issues [53]. Intriguingly, pediatric GBM, despite its aggressive biological nature, shows far fewer focal amplifications and homozygous deletions than its adult counterpart [52]. The strikingly normal genome for one of the most aggressive human cancers highlights the distinct biology of pediatric GBM and HGG, and clearly indicates that alternative pathways to those associated with the traditional cancer hallmarks may be driving oncogenesis in children.

**Chromatin remodeling defects characterize pediatric high grade astrocytomas**

Several groups, including our own, have used next-generation sequencing technologies and integrated the results with copy number, gene expression and DNA
methylation datasets in separate and independent ‘TCGA-like’ pediatric initiatives. This has led to the identification of recurrent gain-of-function somatic mutations in \( H3F3A \) in pediatric GBM at critical residues involved in histone post-translational modifications [9,10,54,55] (Table 2). We further uncovered additional mutations in the histone H3.3 chaperone genes \( ATRX \) and \( DAXX \) [10,56], indicative of altered chromatin remodeling pathways in 44% of pediatric GBM tumors [10]. In a large adult and pediatric glioma cohort comprising 784 tumors ranging from WHO grade I PAs to grade IV GBM, \( H3F3A \) mutations were found to be highly specific to GBM in the pediatric setting (patients aged less than 20 years) [10], with recent studies confirming their specificity to diffuse high-grade tumors but also identifying the presence of the \( H3F3A \) K27M mutation in a small percentage of low-grade diffuse gliomas of the thalamus (1.9% of the tumor series) [20]. Independently, as part of the International Cancer Genome Consortium PedBrain Tumor Project, the \( H3F3A \) K27M mutation was identified in a thalamic PA tumor (1 of 96) in conjunction with \( NF1 \) and an activating \( FGFR1 \) hotspot mutation; a constellation of mutations also seen in 3 of 48 thalamic GBM tumors upon re-analysis, suggesting a potential mechanism for glioma genesis in this brain region [21]. Further to this, individual \( H3F3A \) mutations were also described in distinct age groups, with K27M mutations being restricted to infant and childhood GBM (median age 10.5 years, range 5 to 23 years), and G34R/V mutations defining GBM in adolescents and young adults (median age 18 years, range 9 to 42 years) [9,10]. Interestingly, in the context of DIPG, around 80% of samples carried the K27M mutation in either the non-canonical H3.3 (approximately 60 to 70%) or the canonical H3.1 (approximately 18%), while 80% of thalamic pediatric GBM samples carried the K27M H3.3 mutation, indicative of a midline (diencephalon/thalamus, brainstem, spinal cord) predilection for this specific amino acid substitution [10,11,54].

| Mutation/alterations | Frequency of alteration in adult patients | Frequency of alteration in pediatric patients | Type of alteration | Gene function |
|----------------------|------------------------------------------|---------------------------------------------|-------------------|---------------|
| ATRX/DAXX            | 7%, 26% [56,58] 31%, 34% [10,56]         | LOF mutations                               | Subunits of a chromatin remodeling complex required for H3.3 incorporation at pericentric heterochromatin and telomeres |
| BRAF                 | 0% [83]                                  | Mutations/indels (V600E, A598delInsAT)      | Oncogene          |
| EGFR                 | 20%, 45%[41,46] 6%,26% [10,84]           | Amplifications, GOF mutations (EGFR VIII) and fusions | Receptor tyrosine kinase of the ERBB family |
| FGFR1/3              | 3.1% [85]                                 | GOF mutations and fusions (FGFR1/3 and TACC1/3) | FGF receptors are thought to have a role in the development of the nervous system |
| H3F3A                | 3% [56]                                  | Mutations (K27M and G34R/V)                 | Replication-independent histone H3 variant |
| IDH1/2               | 26%, 5% 12% [47,48,56]                   | GOF recurrent mutations                     | Enzyme that catalyzes the oxidative decarboxylation of isocitrate and, when mutated, produces 2-hydroxyglutarate |
| NF1                  | 18% [41, 46]                             | Deletions and LOF mutations                 | Tumor suppressor gene |
| PIK3R1/PIK3CA        | 10%, 1-4%, 22% [10,41,46]                | Activating mutations (PIK3CA), LOF mutations (PIK3R1) | Involved in the regulation of the PI3K pathway, PTEN, and receptor trafficking |
| SETD2                | 8% [55]                                  | LOF mutations                               | Histone trimethyltransferase specific to H3X36 |
| TP53                 | 32%, 35% [41,46] 54% [10,84]             | Deletions and LOF mutations                 | Tumor suppressor gene |
| PTEN                 | 80%, 82% [43,51] 35% [51]                | Deletions and LOF mutations, chromosome 10p loss | Tumor suppressor gene |
| CDKN2A               | 52% [46]                                 | 13% [10]                                   | Deletions         | Tumor suppressor gene |
| CDK4                 | 14%, 18% [10,46] 0% [10]                 | Amplifications and GOF mutations           | Serine/threonine kinase important for cell cycle progression |
| PDGFR               | 4%,12%, 13% [10,41,46]                   | Amplifications and GOF mutations           | Cell surface tyrosine kinase receptor for the PDGF family |

FGF, fibroblast growth factor; GOF, gain of function; LOF, loss of function; PDGF, platelet-derived growth factor; PI3K, phosphoinositide 3-kinase.
Compound mutations identified in conjunction with H3F3A mutations can give great insight into additional genetic hits required for tumorigenesis. ATRX mutations were reported in association with both K27M and G34R/V mutations in pediatric GBM, with an almost complete concordance in G34R/V-mutant tumors, which were also completely defined by mutations in TP53 [10]. ATRX mutations were present in more than 80% of thalamic K27M H3.3 tumors but, strikingly, were found in barely 10% of brainstem K27M H3.3 tumors, where they seemed to mainly occur in older children with DIPG, further implicating this combination (H3F3A and ATRX mutations) in GBM in older children and adolescents [11]. Recent studies have explored the association between telomerase reverse transcriptase (TERT) promoter mutations and ATRX (shown to correlate with the alternative lengthening of telomeres phenotype in pediatric GBM [10] and pancreatic neuroendocrine tumors [58]). These studies have shown that these alterations appear to be highly mutually exclusive, with 0 of 83 gliomas (across glioma subtypes including GBM, grade II to III astrocytoma, oligodendroglioma and oligoastrocytoma) with TERT promoter mutations demonstrating co-mutation with ATRX (P < 0.0001) [59]. This provides insight into the mechanism of tumorigenesis and the manner in which glioma cells exploit the cellular telomere maintenance machinery.

The reports that uncovered H3.3 mutations in pediatric HGA were the first to identify mutations in a regulatory histone in humans. Except for rare cases, these mutations seem to be specific to HGA [20,21], and have not been identified in any other cancer to date except for one sample from a child with acute lymphoblastic leukemia out of 1,004 leukemias and lymphomas sequenced [60]. Recurrent H3F3A mutations represent the pediatric counterpart of the recurrent IDH mutations identified in young adult GBM, with which they are mutually exclusive [9,10]. Intriguingly, IDH alterations, which are also gain-of-function, heterozygous somatic mutations, have been shown to be initiating events in gliomas [41,47,61] and they also seem to require association with other genetic events to achieve full-blown tumorigenesis. They are associated with two mutually exclusive genetic alterations, TP53 alterations and 1p/19q co-deletions [6,62] that respectively characterize astrocytic and oligodendrogial IDH-mutant gliomas. We [10,11,63] and others [64,65] recently showed that mutations in ATRX characterize IDH- and TP53-mutant astrocytomas in young adults with low- and high-grade tumors and that these ATRX mutations are mutually exclusive with CIC mutations, which characterize oligodendrogial tumors. Strikingly, the oncometabolite produced as an effect of neomorphic IDH mutations has been shown to affect the epigenome and post-translational modification of the specific lysines identified to be directly (K27) or indirectly (K36) affected in pediatric HGG [66-69], as well as to globally perturb DNA methylation patterns [9,42], similar to the impact of each of the H3.3 mutations that were identified [9]. Indeed, the incorporation of adult and pediatric GBM datasets obtained by utilizing the DNA methylation Illumina 450k platform allowed for further sub-classification of GBM across the age spectrum into six robust epigenetic clusters, three of which were defined by epigenetic driver mutations in H3F3A (K27M, G34R/V) or IDH1 [9], alluding to the importance of epigenomic dysregulation in pediatric and young adult HGGs specifically. We recently identified SETD2 mutations in nearly 15% of pediatric and young adult HGGs [55]. SETD2 mediates trimethylation at lysine 36 of histone H3 [70] and mutations in this gene correlated with a global decrease in H3K36me3 levels, thus affecting post-translational modification of the K36 mark, which is indirectly targeted by G34R/V mutations of H3F3A and IDH1 mutations [55,69]. SETD2 mutations occurred exclusively in tumors of the cerebral cortex, paralleling the age range of IDH1-mutant gliomas (SETD2-mutant tumors median age 16 years, range 1 to 58 years) [55]. These findings suggest that in the context of tumors arising in the cerebral cortex in children and young adults, mutations affecting H3K36 methylation appear to predominate, with H3F3A G34R/V, IDH1 and SETD2 mutations defining about half of all pediatric high-grade gliomas of the cerebral cortex [55], whereas mutations affecting K27 (K27M H3.3 or H3.1) predominate in midline pediatric HGGs (Table 2). These findings define a spectrum of tumor heterogeneity with definable age ranges, demonstrating that distinct genetic alterations are associated with unique epigenetic profiles. Integrated profiling and biochemical approaches to elucidating the functional impact of H3F3A, SETD2 and IDH1 mutations are necessary to determine their mechanism of action and provide targets for therapeutic intervention. Recent efforts have demonstrated global decreases in H3K27me3 levels in K27M-mutant pediatric DIPG and HGG tumors [69,71,72], and have shown mechanistically that H3.3 K27M overexpression can cause a global decrease in H3K27me2/me3 levels in a cell-type-independent manner [69,72]. By utilizing in vitro assays with a bio- tinylated H3.3 K27M peptide, Lewis and colleagues [69] provided convincing evidence that global levels of H3K27 trimethylation decrease through binding and inhibition of the H3K27 trimethyltransferase EZH2 (a component of the polycomb repressor complex 2) (Figure 2). Taken together, these findings provide a basis for the striking decrease in global H3K27 trimethylation in the context of H3.3 variant K27M mutations, which comprise only a small percentage of total cellular H3. Also, GBM cell lines possessing H3.3 G34 mutations demonstrate specific
transcriptional programs involved in stem cell fate and forebrain development and differences in the genomic distribution of the histone mark H3K36me3 [73]. In addition, upregulation of MYCN provides a subgroup-specific target in future endeavors towards targeted therapeutics in H3.3 G34R/V-mutant GBM [73] (Figure 2). With further insights into the mechanism of action of H3.3 mutations and their role in subgroup-specific tumorigenesis, individualized translational approaches can be investigated, with the potential for achieving clinical improvements in these patients.

Clinical correlates of epigenetic driver mutations in pediatric high-grade gliomas
Neuroanatomy is integral to assessing patient prognosis, surgical planning, and subsequent functional sequelae in brain tumor treatment. In this regard also, H3F3A mutations are significant, as K27M mutations characterize midline tumors in regions such as the thalamus/diencephalon and brainstem whereas G34R/V mutations are confined to cortical regions of the hemispheres, as we have outlined earlier [9,10]. Studies of DIPG have shown that over 80% of these tumors are defined by recurrent mutations at K27 of H3.3 or H3.1 (K27M) [11]. In addition, K27M H3.3 mutation was associated with decreased overall survival in DIPG patients; data that support the use of stereotactic biopsy and a more personalized approach to attacking this aggressive tumor [11]. Complementary to this, G34R/V mutations in H3.3 and IDH1 R132-mutant tumors, preferentially occurring in cortical areas, appear to be associated with better overall survival than their K27M counterparts, and this comparison of better overall survival in G34-mutant compared with K27M-mutant tumors is also true when controlling for better accessibility to surgical resection in G34-mutant cases [9]. This striking neuroanatomical specificity provides information with regard to the suspected cellular origins of particular GBM subgroups, as regions of the subgranular and subventricular zones are NSC-enriched locations [74]. Recent work in mice, using cell-type-specific lentiviral induction of gliomas, demonstrated subgranular and subventricular but not
cortical location preferences for NSC-mediated tumors [74]. Contrary to this, astrocytic tumors developed in cortical regions, as well as the hippocampus, striatum and subventricular zone [74]. A H3.3 K27M-mutant human DIPG xenograft has recently been shown to express nestin, a marker of NSCs [72]. In addition, differential expression of the OLIG1, OLIG2 and FOXG1 transcription factors between K27M and G34R/V tumors not only provides opportunities for diagnostics, but also provides insight into the cellular origins of these epigenetic driver mutations [9]. It is tempting to hypothesize that H3F3A mutations (K27M and G34R/V) and IDH1 mutations constitute developmental defects and arise in unique precursor cells in different brain regions, explaining their substantial heterogeneity and differing clinical behavior. Taken together, neuroanatomical findings indicating cortical and midline compartments for G34R/V and K27M tumors, respectively, and expression of stem cell and lineage markers suggest unique cellular origins and/or profound reprogramming that is characteristic of each histone mutation.

Re-evaluating pediatric high-grade glioma management with molecular pathology

Recent evidence has allowed clinicians and researchers to glimpse the unique genomic paradigm presented by pediatric HGG tumors. Incorporating these findings into the design of future clinical trials and as companion diagnostics to routine pathology will be essential in evaluating their significance in personalized approaches for patients with these deadly diseases. Large-scale projects in other pediatric central nervous system tumors such as medulloblastoma have permitted the identification of subgroup-specific targets, providing platforms for the development of targeted therapeutics in a personalized manner [35]. Similarly, using evidence provided by recent genomic studies, independent investigations and modeling of epigenetic and gene expression subgroups of GBM tumors and HGGs in both adult and pediatric settings will allow for investigations into mechanisms of tumorigenesis in a subgroup-specific fashion. As such, future in vitro and in vivo models of GBM tumors and HGGs possessing driver mutations, notably those involving RTKs, H3F3A K27M and G34R/V, SETD2 and IDH1 will constitute invaluable tools to enable molecular profiling and eventual drug development and screening. Recent characterization of a conditional IDH1 knock-in mouse model demonstrated a comprehensive recapitulation of DNA methylation and signature histone marks seen in human acute myeloid leukemia, in which IDH1 and IDH2 R132 and R172 mutations, respectively, have been described, in addition to gliomas [68,75]. Such models, which reproduce findings in human tumors, namely alterations in histone and DNA methylation patterns in the context of IDH1 mutation [41,66], permit potentially reliable and accurate platforms for drug screening in pre-clinical research. Notably, recent characterization of a mutant IDH1 inhibitor and its ability to block growth and induce differentiation in IDH1-mutant glioma cells, independent of drastic global DNA methylation changes, raises additional questions about the mechanism of action and oncogenicity of identified epigenetic driver mutations such as IDH1 R132H [76].

Accurate diagnostics and subgrouping enabled by genomic characterization of pediatric HGG tumors presents a potential avenue for further stratifying clinical management. Recent studies have demonstrated the diagnostic potential of H3F3A sequencing owing to the specificity of these mutations for diffuse, overwhelmingly high-grade tumors, albeit with a few exceptions [10,11,20,21,57,77]. In conjunction with immunohistochemical markers of FOXG1 and OLIG2 expression, the identification of K27M- and G34R/V-mutant tumors in parallel with routine molecular pathology analyses presents a potential means of identifying patients possessing these mutations that demonstrate different clinical courses [9]. Recently described IDH1 R132H- [78] and H3.3 K27M-specific [69] antibodies will undoubtedly be of great benefit to neuropathologists complementing histology with translational tools as these become available. In the context of unresectable DIPG tumors, which currently have a dismal prognosis, patients with H3F3A K27M mutations demonstrated worse overall survival than H3F3A wild-type tumors [11]. As mentioned earlier, such findings indicate that stereotactic biopsy and tumor profiling may enable differential clinical management of H3F3A K27M-mutated and wild-type DIPG, which recent studies have shown are markedly distinct at the molecular level [11,69,72]. Additionally, in the context of pathologic biomarker development, recent advances in magnetic resonance detection offer valuable non-invasive approaches; this is exemplified in the context of 2-hydroxyglutarate detection in IDH1-mutant glioma patients by novel magnetic resonance and spectroscopic techniques [79-81]. Taken together, further genomic characterization and modeling of individual epigenetic subtypes of GBM and HGG and subsequent characterization of their clinical correlates may form the basis for stratification of future clinical trials.

Conclusions and future directions

At present, there are no effective therapies for childhood HGG, including GBM and DIPG, and these tumors remain lethal across the age spectrum. Recent genomic studies have succeeded in elucidating novel mutations and biochemical mechanisms at play in these tumors, with further studies into subgroup-specific mechanisms...
forming the next critical step towards improvement in the clinical management of this deadly group of diseases. The identification of driver mutations in H3F3A, ATRX, DAXX, IDH1 and SETD2 has revamped the way we think about HGGs, and has placed chromatin remodeling defects center stage, notably in the context of pediatric and young adult disease [1]. As discussed earlier, recent genomic and epigenomic studies have not only begun to shed light on the subgroups of GBM, but additionally on how these groups vary according to clinical variables, with pediatric and younger adult patients demonstrating driver epigenetic defects, and older patients presenting more frequently with classical defects in RTK and growth-related pathways [9]. This speaks volumes with regard to patient management and the design of future clinical trials: specific patient recruitment and genomic profiling will increasingly be necessary to tackle the many facets of GBM and HGGs. Novel efforts to design therapeutics will undoubtedly benefit as new, exciting studies continue to emerge throughout oncology, outlining the role of epigenetics and histone marks in regulating cellular processes [66,68], the function of dysregulated metabolism in cancer cells [67,82] and, importantly, the interaction of genomics, epigenomics, transcriptomics and metabolomics enabled by the continuous shift towards systems-biology-based approaches. Progress towards better management of patients with these tumors will necessitate a more personalized approach and the cooperation of clinicians, pathologists, researchers and bioinformaticians alike. Identification and mechanistic elucidation of the effects and profiles of driver mutations may form the basis of target discovery, and the development of in vitro and in vivo models will enable functional characterization and drug screening. Following this, translational approaches will enable us to better stratify clinical trials and adopt these molecular tools to maximize the benefits for patients and their families faced with HGG diagnoses.

Abbreviations
DIPG, diffuse intrinsic pontine glioma; GBM, glioblastoma multiforme; HGA, high-grade astrocytoma; HGG, high-grade glioma; H3.3, histone 3.3; MAPK, mitogen-activated protein kinase; NSC, neural stem cell; PA, pilocytic astrocytoma; RTK, receptor tyrosine kinase; TCGA, The Cancer Genome Atlas; YB-1, Y-box protein 1; WHO, World Health Organization.

Competing interests
The authors declare that they have no competing interests.

Acknowledgments
This work was funded in part by Genome Canada and the Canadian Institute for Health Research (CIHR), with co-funding from Genome BC, Genome Quebec, CIHR-ICR (Institute for Cancer Research) and C17, through the Genome Canada/CIHR joint ATID Competition (project title: The Canadian Paediatric Cancer Genome Consortium: Translating next generation sequencing technologies into improved therapies for high-risk childhood cancer). AFIF is supported by a studentship from the CIHR and the McGill University Systems Biology Training Program. NG is the recipient of a studentship award from the Cedars Cancer Institute. NJ is the recipient of a Chercheur Clinicien Senior Award from FRQs and a Next Generation Champion of Genetics' award from the Canadian Gene Cure Foundation.

Author details
1 Departments of Pediatrics and Human Genetics, McGill University and McGill University Health Centre, Montreal, Quebec, Canada, H3H233.
2 Division of Experimental Medicine, McGill University and McGill University Health Centre, Montreal, Quebec, Canada, H3H233.
3 Department of Pathology, Montreal Children’s Hospital, McGill University Health Centre, Montreal, Quebec, Canada, H3H1P3.

Published: 30 July 2013

References
1. Fontebasso AM, Liu XY, Sturm D, Jabado N: Chromatin remodeling defects in pediatric and young adult glioblastoma: a tale of a variant histone 3 tail. Brain Pathol 2013, 23:210-216.
2. Kieran MW, Walker D, Frappaz D, Prados M: Brain tumors: from childhood through adolescence into adulthood. J Clin Oncol 2010, 28:4783-4789.
3. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007, 114:97-109.
4. Ohgaki H, Kleihues P: Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendrogliogial gliomas. / Neuropathol Exp Neurol 2005, 64:479-489.
5. Dolecek TA, Proppe JM, Stoup NE, Kruchko C: CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neurol Oncol 2012, 14 Suppl 1:v-49.
6. Ohgaki H, Kleihues P: Genetic profile of astrocytic and oligodendrogliogial gliomas. Brain Tumor Pathol 2011, 28:177-183.
7. Khourgu-Quang DA, Gerges N, Jabado N: Mutations in histone H3.3 and chromatin remodeling genes drive pediatric and young adult glioblastomas. Med Sci 2012, 28:809-812.
8. Rood BR, MacDonald TJ: Pediatric high-grade glioma: molecular genetic clues for innovative therapeutic approaches. / Neuro Oncol 2005, 78:267-272.
9. Sturm D, Witt H, Hoversvadt V, Khuong-Quang DA, Jones DT, Konemann C, Pfaff E, Tonjes M, Sil M, Bender S, Kool M, Zaparka M, Becker N, Zucknick M, Hielscher T, Liu XY, Fontebasso AM, Rythova M, Albrecht S, Jacob K, Wolter M, Ebinger M, Schuhmann MU, van Meter T, Fruhwald MC, Hauch H, Pekrun A, Radlwinwimer B, Niehues T, von Konorowski G et al: Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 2012, 22:425-437.
10. Schwartzentruber J, Korshunov A, Liu XY, Jones DT, Pfaff E, Jacob K, Sturm D, Fontebasso AM, Quang DA, Tonjes M, Hoversvadt V, Albrecht S, Kool M, Nantel A, Konemann C, Lindroth A, Jager N, Rauchw T, Rythova M, Korbol JO, Hielscher T, Hauser P, Garmani M, Klekner A, Bognar L, Ebinger M, Schuhmann MU, Scheiuen W, Pekrun A, Fruhwald MC et al: Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastomas. Nature 2012, 482:226-231.
11. Khoung-Quang DA, Buczkozkiewicz P, Rakopolous P, Liu XY, Fontebasso AM, Bouffet E, Bartels U, Albrecht S, Schwartzentruber J, Letourneau L, Bourgey M, Bourque G, Montpetit A, Bouveret G, Lepage P, Fleming A, Lighter K, Poon C, deimling A, sturm D, korschunov A, faury D, Jones DT, Majewski J, Pfister SM, Jabado N, Hawkins C: K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol 2012, 124:639-647.
12. Jacob K, Albrecht S, Sollier C, Faury D, Sader E, Montpetit A, Serre D, Hauser P, Garmani M, Bograni L, Hanzely Z, Montes JL, Atkinson J, Farmep J, Bouffet E, Hawkins C, Tabo A, Jabado N: Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours. Br J Cancer 2009, 101:722-733.
13. Jacob K, Quang-Khuong DA, Jones DT, Witt H, Lambert S, Albrecht S, Witt O, Veza C, Shinarin M, Faury D, Garam M, Hauser P, Klekner A, Bognar L, Farmer JP, Montes JL, Atkinson J, Hawkins C, korschunov A, Collins VP, Pfister SM, Tabo A, Jabado N: Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas. Clin Cancer Res 2011, 17:4650-4660.
14. Jones DT, Kociakowski S, Liu L, Pearson DM, Backlund LM, Ichimura K, Collins VP: Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res 2008,
irinotecan in recurrent glioblastoma multiforme. 

Bevacizumab plus temozolomide in glioblastoma. 

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. 

Cloughesy TF, Sawyers CL, Mischel PS, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Ellison A, Clifford SC, Versteeg R. 

Integrated genomics identifies five medulloblastoma subtypes with distinct genetic pathways, patient signatures and clinical pharmacological features. 

PloS One 2008, e30038. 

Medulloblastoma pathways comprise four distinct molecular variants. 

J Clin Oncol 2011, 29:1408-1414. 

Parsons DW, Li M, Zhang X, Jones S, Leary RJ, Lin JC, Boca SM, Carter H, Samayoa J, Bettgowda C, Gallia GL, Jallo QJ, Binder ZA, Nikolsky Y, Hartigan J, Smith DR, Gerhard DS, Fults DW, VandenBerg S, Berger MS, Marie SK, Shinjo SM, Ciara C, Phillips PC, Minturn JE, Biegel JA, Judkins AR, Resnick AC, Storm PB, C burr T et al. 

The genetic landscape of the childhood cancer medulloblastoma. 

Science 2011, 331:435-439. 

Taylor MD, Northcott PA, Korshunov A, Remes G, Cho YJ, Clifford SC, Eberhart CG, Parsons DW, Rutkowski S, Gajjar A, Ellison DW, Lichter P, Gilbertson RJ, Pomerol SL, Kool M, Pfister SM. 

Molecular subtypes of medulloblastoma: the current consensus. 

Acta Neuropathol 2012, 123:465-472. 

Hinesen DT, Hutter N, Kool M, Sivakumar V, Cho YJ, Pugh TJ, Hovestadt V, Stutz AM, Rasch T, Wernhardt HJ, Ryzhova M, Bender S, Sturm D, Pieker S, Hin P, Pieker S, Wernhardt B, Sartorius SM, Tizardis T, Weissenfeld J, Raeder B, Avi M, Armitaglavi A, Zapatake M, Weber UD et al. 

Dissecting the genomic complexity underlying medulloblastoma. 

Nature 2012, 488:100-105. 

Northcott PA, Shih DJ, Peacock J, Gazzeri L, Moriass Y, Zichner T, Stutz AM, Korshunov A, Reindl J, Schmacher SE, Berothul EM, Rutkowski S, Eison DW, Marshall CR, Lencie LA, Mack S, Dubu T, Yao Y, Rasmussen M, Luu B, Roderier A, Cavalli W, Wang X, Remes G, Wu X, Chu YH, Chu E, Chua H, Corbett RD, Hoard GR, Jackman SD et al. 

Subgroup-specific structural variation across 1,000 medulloblastoma genomes. 

Nature 2012, 488:449-56. 

Robison G, Parker M, Kanenburu TA, Lu C, Chen X, Ding L, Feniu TN, Hulendur E, Wei L, Zhu X, Chiallo N, Baker SJ, Hutter R, Kravick C, Curley N, Thrusenkatam B, Wang J, Wu L, Ruchi M, Hong X, Beckford J, Gupta P, Ma J, Easton J, Vadobara D, Obar-Thomas A, Lin T, Li S, Pounds S, Pugh J et al. 

Novel mutations target distinct subgroups of medulloblastoma. 

Nature 2012, 488:43-48. 

Gibson P, Tong Y, Robinson G, Thompson MC, Curtin DS, Eden C, Kanenburu TA, Hogg T, Poppleton H, Martin J, Finkelstein D, Pounds S, Weiss A, Patay Z, Scorssin M, Ogg R, Pei Y, Y Zi, Brun S, Lee X, Zindy F, Lindsey J, Taketo MM, Beppo SA, Sanfo PA, Gajjar A, Clifford KC, Rousell MF, Kincannon PJ, Gutmanner DH et al. 

Subtypes of medulloblastoma have distinct developmental origins. 

Nature 2010, 468:1095-1099. 

Pugh TJ, Weaverinade SC, Archer TC, Pomeranz Krummel DA, Auclair D, Bohiochico J, Canoro MO, Carter SL, Cibulskis K, Erlich RL, Greulich H, Lawrence MS, Lennin NN, McKenna A, Meldrim J, Ramos AH, Ross MG, Russ C, Spheller E, Svanhvaena A, Soglobof B, Sojanov P, Tamayo P, Mesirov JP, Amanu V, Teider N, Sengupta S, Francois JP, Northcott PA, Taylor MD et al. 

Medulloblastoma exome sequencing uncovers subtype-specific genomic mutations. 

Nature 2012, 488:106-110. 

Northcott PA, Jones DT, Kool M, Robinson GW, Gilbertson RJ, Cho YJ, Pomerol SL, Korshunov A, Lichter P, Taylor MD, Pfister SM. 

Medulloblastomias: the end of the beginning. 

Nat Rev Cancer 2012, 12:819-834. 

Witt HK, Mack SC, Ryzhova M, Bender S, Sil M, Isselbrier R, Benner A, Hieserl T, Milder T, Remke M, Jones DT, Northcott PA, Gazza L, Berandan KC, Wernhardt B, Ayo Y, Roberts SS, Massimi L, Van Meter T, Weiss WA, Gappa N, Grakojwika W, Lach B, Cho YJ, von Deimling A, Kuloski AE, Witt W, Bader GD, Hawkins CE, Taboni U et al. 

Delineation of two clinically and molecularly distinct subtypes of posterior fossa encondroma. 

Cancer Cell 2011, 20:143-157. 

Verhage RA, Hoodley KA, Purdcent E, Wang Y, QY, Ylikson M, Miller CR, Ding L, Golub T, Mesirov JP, Alev X, Lawrence M, Okefny M, Tamayo P, Weir BA, Gabriel S, Winckler W, Gupta S, Jakkula L, Feller HS, Hirden JS, Jackman J, Sarkaria NN, Brennan C, Kahn A, Spellman PT, Wilson RK, Speed TP, Gray JW, Meyerson M et al. 

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in POFDRA, IDHD, GFR, and ID1A. 

Cancer Cell 2011, 19:758-710.
42. Nourshmelh M, Weisenberger DJ, Diesfeld K, Phillips HS, Pupeza K, Berman BP, Pan F, Pellkoski CE, Sulman EP, Bhat KP, Verhaak RG, Hoadley KA, Hayes DE, Perou CM, Schmidt HK, Ding L, Wilson RK, Van Den Berg D, Shen H, Bengtsson H, Neuville P, Cope LM, Buckley J, Herman JG, Baylin SB, Laird PW, Aldape K. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. *Cancer Cell* 2010; 17:510-522.

43. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroueo L, Williams PM, Modrusan Z, Feuerstein BG, Aldape K. Molecular subclasses of high-grade glioma predict progression, delineate a pattern of disease progression, and resemble stages in neurogenesis. *Cancer Cell* 2006, 9:151-173.

44. Faury D, Nantel A, Dunn SE, Guert GC, Haque T, Hauser P, Garami M, Bognar L, Hanzely Z, Liberski PP, Lopez-Aguilar E, Valera ET, Tong L, Carret AS, Del Maestro RF, Gleave M, Montes JL, Pietts T, Albrecht B, Jabado N. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. *J Clin Oncol* 2007, 25:1196-1206.

45. Haque T, Faury D, Albrecht S, Lopez-Aguilar E, Hauser P, Garami M, Hanzely Z, Bognar L, Del Maestro RF, Atkinson J, Nantel A, Jabado N. Gene expression profiling from formalin-fixed paraffin-embedded tumors of pediatric glioblastoma. *Clin Cancer Res* 2007, 13:6284-6292.

46. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature* 2008, 455:101-1068.

47. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu I, Mital D, Ligon K, McLendon R, St sniper J, Van den Berg P, Yu J, Ding L, Shen H, Hidalgo M, Stambolic V, Stupp R, Stein H, Antonescu CR, Papadopoulos N, Parmigiani G et al. An integrated genomic analysis of human glioblastoma multiforme. *Science* 2008, 321:1807-1812.

48. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Koss I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Albrecht S, Croul S, Jones DT, Kool M, Tonjes M, Reifenberger G, Faury D, Hanzely Z, Liberski PP, Lopez-Aguilar E, Valera ET, Ling L, Carret AS, Del Maestro RF, Gleave M, Montes JL, Pietts T, Albrecht B, Jabado N. Gene expression profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. *J Clin Oncol* 2007, 25:1196-1206.

49. Gerges GM, Genome Medicine 5, 2013, W Qu HQ, Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pupeza K, Berman BP, Pan F, Pellkoski CE, Sulman EP, Bhat KP, Verhaak RG, Hoadley KA, Hayes DE, Perou CM, Schmidt HK, Ding L, Wilson RK, Van Den Berg D, Shen H, Bengtsson H, Neuville P, Cope LM, Buckley J, Herman JG, Baylin SB, Laird PW, Aldape K. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. *Cancer Cell* 2010, 17:510-522.

50. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroueo L, Williams PM, Modrusan Z, Feuerstein BG, Aldape K. Molecular subclasses of high-grade glioma predict progression, delineate a pattern of disease progression, and resemble stages in neurogenesis. *Cancer Cell* 2006, 9:151-173.

51. Faury D, Nantel A, Dunn SE, Guert GC, Haque T, Hauser P, Garami M, Bognar L, Hanzely Z, Liberski PP, Lopez-Aguilar E, Valera ET, Tong L, Carret AS, Del Maestro RF, Gleave M, Montes JL, Pietts T, Albrecht B, Jabado N. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. *J Clin Oncol* 2007, 25:1196-1206.

52. Gerges GM, Genome Medicine 5, 2013, W Qu HQ, Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pupeza K, Berman BP, Pan F, Pellkoski CE, Sulman EP, Bhat KP, Verhaak RG, Hoadley KA, Hayes DE, Perou CM, Schmidt HK, Ding L, Wilson RK, Van Den Berg D, Shen H, Bengtsson H, Neuville P, Cope LM, Buckley J, Herman JG, Baylin SB, Laird PW, Aldape K. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. *Cancer Cell* 2010, 17:510-522.

53. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroueo L, Williams PM, Modrusan Z, Feuerstein BG, Aldape K. Molecular subclasses of high-grade glioma predict progression, delineate a pattern of disease progression, and resemble stages in neurogenesis. *Cancer Cell* 2006, 9:151-173.
glioblastomas. Brain Pathol 2013. doi: 10.1111/bpa.12042.
72. Chan KM, Fang D, Gan H, Hashizume R, Yu C, Schroeder M, Gupta N, Mueller S, James CD, Jenkins R, Sarkaria J, Zhang Z. The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev 2013, 27:985-990.
73. Byrke L, Mackay A, Nandhabalanan M, Burford A, Jury A, Popov S, Bax DA, Carvalho D, Taylor KR, Vinci M, Bajrami I, McConnell IM, Lord CJ, Reis RM, Hargrave D, Ashworth A, Workman P, Jones C. Histone H3.3 mutations drive pediatric glioblastoma through upregulation of MYCN. Cancer Discov 2013. doi: 10.1158/2159-8290.
74. Friedmann-Morvinski D, Bushong EA, Ke E, Sada Y, Marumoto T, Singer O, Ellisman MH, Verma IM. Dedifferentiation of neurons and astrocytes by oncogenes can induce gliomas in mice. Science 2012, 338:1080-1084.
75. Figueiredo MA, Abdel-Wahab O, Lu C, Ward PS, Patel J, Shih A, Li Y, Bhagwat N, Vasanthakumar A, Fernandez HF, Tallman MS, Sun Z, Wolniak K, Peeters JK, Liu W, Choe SE, Fantin VR, Paietta E, Lowenberg B, Licht JD, Godley LA, Delwel R, Valk PJ, Thompson CB, Levine RL, Melnick A. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2013, 118:599-601.
76. Rohde D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, Tsoi J, Clark O, Oldrini B, Komisopoulou E, Kuni K, Pedraza A, Schalm S, Silverman L, Miller A, Wang F, Yang H, Chen Y, Kernytsky A, Rosenblum MK, Liu W, Choe SE, Fantin VR, Paietta E, Lowenberg B, Licht JD, Godley LA, Delwel R, Valk PJ, Thompson CB, Levine RL, Melnick A. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013, 340:626-630.
77. Gessi M, Gelien GH, Hammes J, Domer E, Muhlen AZ, Waha A, Petsch T. H3.3 G34R mutations in pediatric primitive neuroectodermal tumors of central nervous system (CNS-PNET) and pediatric glioblastomas: possible diagnostic and therapeutic implications? J Neurooncol 2013, 112:67-72.
78. Capper D, Zentgraf H, Balis J, Hartmann C, von Deimling A. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol 2009, 118:599-601.
79. Elkhaleld A, Albart LE, Phillips JJ, Yoshihara HA, Parvataneni R, Srinivasan R, Bourne G, Berger MS, Chang SM, Cha S, Nelson SJ. Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas. Sci Transl Med 2012, 4:116ra115.
80. Andronesi OC, Kim GS, Gerster E, Batchelor T, Tzika AA, Fantin VR, Vander Heiden MG, Sorensen AG. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med 2012, 4:16ra114.
81. Metellus P, Figarella-Branger D. Magnetic resonance metabolic imaging of glioma. Sci Transl Med 2012, 4:161ps111.
82. Leprrivier G, Remke M, Rotblat B, Dubuc A, Mateo AR, Kool M, Agnihotri S, El-Naggar A, Yu B, Prakash Somasekhharan S, Faubert B, Bried B, Tognon CE, Mathers J, Ri A, Barokas A, Kwook B, Bowden M, Smith S, Wu X, Konshunov A, Hilleker-T, Northcott PA, Galpin JD, Ahern CA, Wang Y, McCabe MG, Collins VP, Jones RG et al. The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell 2013, 153:1064-1079.
83. Schindler G, Capper D, Meyer J, Janzarik W, Osman H, Herold-Mende C, Schmieder-Morvinski D, Iavarone A, Wiedenmann B, Wesseling P, Mawrin C, Hasselblatt M, Louis DN, Konshunov A, Pfister S, Hartmann C, Paulus W, Reifenberger G, von Deimling A. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 2011, 121:397-405.
84. Ganig I, Santosh V, Arandth B, Chandramouli BA, Sastry Kolluri VR. Expression of p53, EGFR, pRb and bcl-2 proteins in pediatric glioblastoma multiforme: a study of 54 patients. Pediatr Neurol 2005, 31:292-299.
85. Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A, Liu EM, Reichel J, Porrati P, Pellegrata S, Qu K, Gao Z, Ceccarelli M, Riccardi R, Brat DJ, Guha A, Dalpe K, Golfinos JG, Zagg D, Mikkelson T, Finocchio G, Lasorella A, Rabadian R, lavone A. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 2012, 337:1231-1235.
86. Pollack IF, Hamilton RL, Sobol RW, Nikolofora MN, Lyons-Weiler MA, Laframboise WA, Burger PC, Brat DJ, Rosenblum MK, Holmes EL, Zhou T, Jakacci R. IDH1 mutations are common in malignant gliomas arising in adolescents: a report from the Children’s Oncology Group. Childs Nerv Syst 2011, 27:97-94.